1. SERA reported $16,000 revenue in Q3 2025, down from $29,000 in Q3 2024. 2. Engaged in Medicaid pilot in Nevada, expanding payer partnerships across thirteen states. 3. Planned publication of pivotal PRIME study results and further economic analyses this year. 4. Dr. Tiffany Inglis appointed as Chief Medical Officer to drive growth in maternal health. 5. Cash reserves of $102.4 million expected to fund operations until 2028.
The expansion in partnerships and upcoming data publications indicate potential revenue growth. Historical increases in stock prices often follow successful pilot projects and positive study outcomes.
SERA's strategic initiatives in federal Medicaid partnerships and leadership enhancements are critical for future revenue growth. The financial results and pilot program could significantly affect investor sentiment.
The initiatives in Medicaid and study results could take time to materialize into tangible revenue growth, similar to past healthcare innovators experiencing delayed market adoption.
SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025.
Third Quarter and Recent Highlights:
"We are seeing commercial traction from the groundwork we have laid, anchored by the results from our pivotal PRIME study," stated Zhenya Lindgardt, President and CEO of Sera Prognostics. "These data are driving meaningful engagement with managed Medicaid and other key stakeholders, including the launch of our first Medicaid pilot in Nevada. We are also advancing discussions with managed Medicaid plans in additional states, representing a strong commercial opportunity, covering 33% of U.S. births and 35% of Medicaid births annually. Beyond this first wave, we've initiated outreach to the next tier of target states, expanding our footprint of states in discussion. In addition, we are actively engaged with payers who are both regional and national in scope. We believe these early signals of market engagement, combined with the scale of the opportunity, position us well to deliver meaningful impact for patients and long-term value for shareholders."
"We're seeing strong early traction with payers, providers, and State Medicaid agencies, who recognize PreTRM's predictive accuracy and the 20% reduction in NICU admissions," said Dr. Tiffany Inglis, Chief Medical Officer of Sera Prognostics. "These partners see clear potential to improve maternal and neonatal outcomes while significantly lowering costs driven by preterm birth. Securing broad coverage at the employer, plan, and state levels is the critical next step to unlocking this value at scale. We are actively advancing these discussions to drive adoption and transform prenatal care."
Third Quarter 2025 Financial Results
Third quarter 2025 revenue was $16,000 compared to $29,000 for the third quarter of 2024.
As of September 30, 2025 deferred revenue increased by $100,000 driven by the prepayment received from the first Medicaid pilot in Nevada.
Total operating expenses were $9.0 million, compared to $8.9 million for the same period in 2024.
Research and development expenses for the third quarter of 2025 were $3.3 million, compared to $3.5 million for the third quarter of 2024 primarily due to lower clinical study costs following the completion of the pivotal PRIME study and as the Company shifts toward commercialization.
Selling, general and administrative expenses for the third quarter of 2025 were $5.7 million, up from $5.4 million for the prior-year period as Sera continued to carefully invest in targeted commercial activities and strategic headcount additions, while building market awareness in preparation for the publication of PRIME study data.
Net loss for the quarter was $7.8 million and down from $7.9 million for the same period a year ago as the Company continued its focus on managing our capital resources ahead of expected revenue expansion in the future.
As of September 30, 2025, the Company had cash, cash equivalents, and available-for-sale securities of approximately $102.4 million, which Sera expects to fund the company across significant adoption and commercial milestones through 2028.
Conference Call Information
Sera Prognostics will host a corresponding conference call and live webcast today to discuss third quarter 2025 operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing the following:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link: https://app.webinar.net/1qop01GkwO2
Live audio of the webcast will be available online from the Investors page of the Company's website at www.sera.com. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2024 March of Dimes Report Card shows that, for the last six consecutive years, more than one in ten infants is born prematurely in the United States. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to engaging with multiple payers across thirteen states, collectively representing a significant opportunity; early signals of market engagement; the Company being well positioned to drive meaningful adoption in target states and beyond; publishing the full study results of the PRIME study this year; swiftly publishing additional data on health economic benefits, sub-population analysis and Medicaid expected cost-saving benefits of the PreTRM Test; accelerating customer onboarding and clinical integration; commercial traction during this foundational growth period; meaningful engagement with managed Medicaid and other key stakeholders; discussions with managed Medicaid plans representing a strong commercial opportunity, covering 33% of U.S. births and 35% of Medicaid births annually; active engagement with payers with both regional and national scope; delivering meaningful impact for patients and long-term value for shareholders; advancing discussions to secure broad coverage at the employer, plan, and state levels and to drive adoption and transform prenatal care; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Contacts:
Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043
Media Contact
Bridget Mahoney at Allison Worldwide
sera@allisonworldwide.com
+1 (716) 868-7505
SERA PROGNOSTICS, INC. | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenue | $ | 16 | $ | 29 | $ | 71 | $ | 53 | ||||||||
Operating expenses: | ||||||||||||||||
Cost of revenue | 41 | 13 | 122 | 50 | ||||||||||||
Research and development | 3,284 | 3,502 | 9,955 | 11,591 | ||||||||||||
Selling and marketing | 1,592 | 1,181 | 4,883 | 3,507 | ||||||||||||
General and administrative | 4,079 | 4,195 | 12,661 | 12,117 | ||||||||||||
Total operating expenses | 8,996 | 8,891 | 27,621 | 27,265 | ||||||||||||
Loss from operations | (8,980) | (8,862) | (27,550) | (27,212) | ||||||||||||
Interest expense | (2) | (5) | (8) | (22) | ||||||||||||
Other income, net | 1,168 | 948 | 3,511 | 2,915 | ||||||||||||
Net loss | $ | (7,814) | $ | (7,919) | $ | (24,047) | $ | (24,319) | ||||||||
Net loss per share, basic and diluted | $ | (0.16) | $ | (0.24) | $ | (0.51) | $ | (0.74) | ||||||||
Weighted-average shares outstanding, basic and diluted | 49,525,108 | 33,522,726 | 46,880,876 | 32,894,191 | ||||||||||||
SERA PROGNOSTICS, INC. | ||||||||
September 30, | December 31, | |||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 4,081 | $ | 4,043 | ||||
Marketable securities | 39,223 | 42,193 | ||||||
Accounts receivable | 14 | 34 | ||||||
Prepaid expenses and other current assets | 1,173 | 1,330 | ||||||
Total current assets | 44,491 | 47,600 | ||||||
Property and equipment, net | 1,032 | 1,239 | ||||||
Long-term marketable securities | 59,080 | 21,973 | ||||||
Intangible assets, net | 939 | 1,026 | ||||||
Other assets | 2,583 | 737 | ||||||
Total assets | $ | 108,125 | $ | 72,575 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,037 | $ | 1,969 | ||||
Accrued and other current liabilities | 2,141 | 2,384 | ||||||
Finance lease obligation, current portion | 3 | 194 | ||||||
Deferred revenue | 20,319 | 20,223 | ||||||
Total current liabilities | 23,500 | 24,770 | ||||||
Finance lease obligation, net of current portion | — | 2 | ||||||
Operating lease obligation, net of current portion | 2,443 | – | ||||||
Total liabilities | 25,943 | 24,772 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Common stock, Class A and Class B | 4 | 3 | ||||||
Additional paid-in capital | 385,751 | 327,534 | ||||||
Accumulated other comprehensive income | 268 | 60 | ||||||
Accumulated deficit | (303,841) | (279,794) | ||||||
Total stockholders' equity | 82,182 | 47,803 | ||||||
Total liabilities and stockholders' equity | $ | 108,125 | $ | 72,575 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-reports-third-quarter-2025-financial-results-302614822.html
SOURCE Sera Prognostics, Inc.